Atamestane

Drug Profile

Atamestane

Alternative Names: Biomed 777; SH 489; ZK 95639

Latest Information Update: 11 Oct 2007

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Intarcia Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Breast cancer

Most Recent Events

  • 31 Jan 2005 Intarcia Therapeutics has completed enrolment in the first phase III trial (Biomed 777-CLP-29 study) for Breast cancer in the US, Canada, Russia and Ukraine
  • 31 Dec 2004 Intarcia Therapeutics has initiated enrolment in the CAT study for Breast cancer in the US and Europe
  • 02 Dec 2004 This compound is still in active development for Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top